mycoplasma | GenomeWeb

mycoplasma

The firm plans to submit the Mycoplasma genitalium test to the FDA in 2017 and has entered an agreement with the CDC for test evaluation. 

The test is an improved version of one that was approved three years ago, and runs on the firm's illumigene molecular diagnostics platform.

A University of Alabama, Birmingham team used the Illumina MiSeq platform to perform next-generation sequencing on 15 strains of M. pneumoniae

Roche said this week that the Canadian Health Authority has accepted the use of its PCR-based mycoplasma detection test MycoTool for release testing of an undisclosed Roche biological product.

NEW YORK (GenomeWeb News) – Roche announced today that the Canadian Health Authority has accepted the use of its mycoplasma detection tool for "release testing" of one of the firm's undisclosed biological products.

Roche said this week that the US Food and Drug Administration has accepted the use of its PCR-based mycoplasma detection test for release testing of an undisclosed Roche biopharmaceutical product.

NEW YORK (GenomeWeb News) – Roche said today that the US Food and Drug Administration has accepted the use of Roche's PCR-based mycoplasma detection test for release testing of a Roche biopharmaceutical product.

The new program applies core technologies from across the company to combine one sample-preparation step with one instrument platform for real-time PCR based detection of Mycoplasma, vesivirus 2117, and mouse minute virus.

Millipore claims that its test, which incorporates transcription-mediated amplification technology developed by Gen-Probe offshoot Roka Bioscience, provides a few advantages over PCR-based Mycoplasma testing.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.